Edgewise Therapeutics Inc

NASDAQ EWTX

Download Data

Edgewise Therapeutics Inc Return on Net Assets (RONA) 3 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: 13.85%

Edgewise Therapeutics Inc Return on Net Assets (RONA) 3 year CAGR is 13.85% for the Trailing 12 Months (TTM) ending March 31, 2024. Return on net assets measures the profitability of a company relative to its net assets, which include total non-current assets and working capital. It is calculated by dividing the net income by the sum of total non-current assets and working capital. This ratio indicates the return generated for each unit of net asset investment made by the company. A higher return on net assets suggests better profitability and efficient utilization of the company's asset base. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Edgewise Therapeutics Inc Return on Net Assets (RONA) for the Trailing 12 Months (TTM) ending March 31, 2023 was -2.69%, a -19.91% change year over year.
  • Edgewise Therapeutics Inc Return on Net Assets (RONA) for the Trailing 12 Months (TTM) ending March 31, 2022 was -2.24%, a -25.27% change year over year.
  • Edgewise Therapeutics Inc Return on Net Assets (RONA) for the Trailing 12 Months (TTM) ending March 31, 2021 was -1.79%.
NASDAQ: EWTX

Edgewise Therapeutics Inc

CEO Dr. Kevin Koch Ph.D.
IPO Date March 26, 2021
Location United States
Headquarters 3415 Colorado Avenue, Boulder, CO, United States, 80303
Employees 92
Sector Healthcare
Industry Biotechnology
Description

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Similar companies

IPSC

Century Therapeutics Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

ACET

Adicet Bio Inc

NA

NA

VOR

Vor Biopharma Inc

NA

NA

DSGN

Design Therapeutics Inc

NA

NA

ELYM

Eliem Therapeutics Inc

NA

NA

HOWL

Werewolf Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email